Avineuro Announced Advancing Potent Small Molecule for Treatment of Alzheimer's Disease to Clinical Development
Posted on: Monday, 3 November 2008, 09:00 CST
SAN DIEGO, Nov. 3 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today the completion of preclinical studies of AVN-101, a potent small molecule for treatment of Alzheimer's disease. These studies demonstrate that AVN-101 is safe and well tolerated, and that it has a favorable pharmacokinetic profile. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-101 into clinical trials in Q1 2009. Results of the studies will be presented at the 9th International Conference -- AD/PD 2009 -- Prague, Czech Republic, March 11-15, 2009.
About Avineuro Pharmaceuticals, Inc.:
Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.
Avineuro Pharmaceuticals, Inc.
CONTACT: Yan Lavrovsky, CEO of Avineuro Pharmaceuticals, Inc.,+1-858-436-1537, fax, +1-858-228-9798, ylavrovsky@avineuro.com
Web site: http://www.avineuro.com/
Source: PRNewswire
Related Articles
- CNCB Post Graduate Studies in Clinical Nutrition (PGSCN) Program is Now Available Online
- Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting
- Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimer's Disease.
- Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
- Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
- Arena Pharmaceuticals Initiates Phase 1 Clinical Trial Program of APD791 for the Treatment of Arterial Thrombosis
- Arena Pharmaceuticals Initiates Phase 2 Clinical Trial of APD125 for the Treatment of Insomnia
- Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of SNS-595 in Ovarian Cancer
- Optimer Pharmaceuticals Initiates Phase 3 Clinical Trials of OPT-99 for the Treatment of Gastroenteritis
- New Study Demonstrates Clinical Efficacy of Telithromycin Superior to Standard First-Line Antibiotic Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia (CAP)
 |
 |
User Comments (0)
RSS Feeds